Repurposing insights: experimental and pharmacological approach on L-Captopril and Dimercaprol as metallo-β-lactamase inhibitors

Clicks: 1
ID: 315342
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #205 of 208 articles by views in FEMS microbiology letters

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The design of specific inhibitors of metallo-β-lactamase (MBL) is one of the priority research lines due to the spread of carbapenem resistant bacterial strains which limits therapeutic options. In parallel, the investigation of new uses of known medicines is prompted by regulatory agencies. In this work, the potential MBL inhibitory potency of L-captopril (an antihypertensive drug) and dimercaprol (used in poisoning by metals) was investigated in a clinical collection of Enterobacterales and Pseudomonas spp. In addition, a comprehensive review of the available literature was conducted, to discuss jointly new and previously available data. The results indicate that activity of imipenem and meropenem combined with 400 mg/L is restored for > 80% and 60%, respectively, for Enterobacterales strains, but not in the Pseudomonas group. Dimercaprol had a limited activity in both bacterial groups. Based on these promising results of L-captopril, pharmacological calculations were performed. It is concluded that the repurposing objective could not be achieved as the overall data indicated that the concentrations of captopril required to achieve carbapenemase inhibitory activity in vivo are higher than maximum used in treatment. Communication of negative results would help to discontinue active current research on L-captopril and should focus on other potential MBL inhibitors.
Reference Key
openalex_W7162869929 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Iciar Rodríguez-Avial, Sthefany Torres, Yuri Puglla, Laura PÉREZ-MARTÍN, Juan-Luis Sebastianes, Alberto Delgado‐Iribarren, Esther Culebras, María-José Valderrama
Journal FEMS microbiology letters
Year 2026
DOI
10.1093/femsle/fnag064
URL
https://doi.org/10.1093/femsle/fnag064
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.